UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options and sold the resulting 9,500 UTHR common shares for roughly $4.7 million via a 10b5‑1 plan.

On September 3, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised two tranches of stock options for 8,910 and 590 shares of common stock at exercise prices of $135.42 and $117.76 per share, respectively, then sold a total of 9,500 shares of the resulting common stock in multiple open‑market transactions at prices ranging from approximately $479.07 to $491.25 per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan. The gross value of the sales was roughly $4.66 million, while the intrinsic gain versus the option exercise prices is even higher, and the trust’s indirect beneficial ownership after these transactions stood at approximately 332,223 shares (plus other indirect and direct holdings noted in the footnotes). The option exercises relate to awards that vested in equal installments in 2021–2023 and expire in March 2027, and the 10b5‑1 plan contemplates further option exercises and sales up to 1,734,410 options or through December 31, 2026. Overall, the filing reflects a sizable, but pre‑planned, monetization of equity rather than a new discretionary purchase.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000135

Alert Tier

7